# A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

Study · id `cardio:ct-nct01334918` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01334918](<https://clinicaltrials.gov/study/NCT01334918>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01334918

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

## Technical summary

Registry record NCT01334918. Randomized; no masking; primary purpose diagnostic. Start 2011-04-26 (actual); primary completion 2012-07-02 (actual). Results posted on 2013-09-18.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose diagnostic
- Phase: Phase 2
- Enrolled: 124 participants (enrolled count; ClinicalTrials.gov record NCT01334918, source copy `cardio:ctgov-nct01334918-2024-12-04`, retrieved 2026-10-26)
- Started: 2011-04-26 (actual) (ClinicalTrials.gov record NCT01334918, source copy `cardio:ctgov-nct01334918-2024-12-04`, retrieved 2026-10-26)
- Primary completion: 2012-07-02 (actual) (ClinicalTrials.gov record NCT01334918, source copy `cardio:ctgov-nct01334918-2024-12-04`, retrieved 2026-10-26)
- Completion: 2012-07-02 (actual) (ClinicalTrials.gov record NCT01334918, source copy `cardio:ctgov-nct01334918-2024-12-04`, retrieved 2026-10-26)
- Results first posted: 2013-09-18 (ClinicalTrials.gov record NCT01334918, source copy `cardio:ctgov-nct01334918-2024-12-04`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01334918, source copy `cardio:ctgov-nct01334918-2024-12-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01334918-2024-12-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
- Condition: Coronary Artery Disease (CAD)
- Intervention (Drug): regadenoson
- Intervention (Radiation): technetium Tc99m sestamibi /technetium Tc99m tetrafosmin
- Intervention (Radiation): Contrast
- Intervention (Procedure): Single Photon Emission Computed Tomography
- Intervention (Procedure): Multidetector Computed Tomography
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: 7fdf004e46ac9f62805d6bba6e14f4bb685e8580aaa220da330c0f4bb207f0eb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
